Cognitive and behavioural assessment in clinical trials: when should they be done?
about
Cognitive Effects of Low-dose Topiramate Compared with Oxcarbazepine in Epilepsy PatientsDeterioration.Comparison of cognitive effects of lamotrigine and oxcarbazepine in epilepsy patients.Turning down the volume: Astrocyte volume change in the generation and termination of epileptic seizures.Impaired verbal fluency under topiramate--evidence for synergistic negative effects of epilepsy, topiramate, and polytherapy.
P2860
Cognitive and behavioural assessment in clinical trials: when should they be done?
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Cognitive and behavioural assessment in clinical trials: when should they be done?
@ast
Cognitive and behavioural assessment in clinical trials: when should they be done?
@en
Cognitive and behavioural assessment in clinical trials: when should they be done?
@nl
type
label
Cognitive and behavioural assessment in clinical trials: when should they be done?
@ast
Cognitive and behavioural assessment in clinical trials: when should they be done?
@en
Cognitive and behavioural assessment in clinical trials: when should they be done?
@nl
prefLabel
Cognitive and behavioural assessment in clinical trials: when should they be done?
@ast
Cognitive and behavioural assessment in clinical trials: when should they be done?
@en
Cognitive and behavioural assessment in clinical trials: when should they be done?
@nl
P1433
P1476
Cognitive and behavioural assessment in clinical trials: when should they be done?
@en
P2093
Aldenkamp AP
P304
155-7; discussion 159-61
P356
10.1016/S0920-1211(01)00244-3
P577
2001-05-01T00:00:00Z